EP2280721
Ónæmismeðferð sem byggir á Indólamín 2,3-Díoxýgenasa
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.4.2009EP published:
15.11.2017EP application number:
09753556.1
EP translation filed:
26.1.2018Grant published:
15.3.2018EPO information:
European Patent Register
Max expiry date:
16.4.2029Expiry date:
16.4.2026Next due date:
30.4.2026
Title:
INDOLEAMINE 2, 3-DIOXYGENASE BASED IMMUNOTHERAPY
Timeline
Today
17.4.2009EP application
15.11.2017EP Publication
26.1.2018Translation submitted
15.3.2018Registration published
16.4.2026Expires
Owner
Name:
IO BIOTECH ApSAddress:
c/o COBIS Ole Maaløes Vej 3, 2200, Copenhagen N, DK
Inventor
Name:
ANDERSEN, Mads, HaldAddress:
Nærum, DK
Name:
STRATEN, Per, ThorAddress:
Hvidovre, DK
Agent
Name:
Tego ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
200800565Date:
17.4.2008Country:
DK
Classification
Categories:
A61K 38/17, A61K 38/08, A61K 38/10, A61K 38/19, A61K 38/20, A61K 45/06, C12N 9/02, A61K 38/44, A61K 39/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 5.3.2018
Expires: 16.4.2019
Payer: Árnason Faktor
Number: 11
Paid: 8.3.2019
Expires: 16.4.2020
Payer: Árnason Faktor
Number: 12
Paid: 10.3.2020
Expires: 16.4.2021
Payer: Árnason Faktor ehf.
Number: 13
Paid: 10.3.2021
Expires: 16.4.2022
Payer: Árnason Faktor ehf.
Number: 14
Paid: 10.3.2022
Expires: 16.4.2023
Payer: Árnason Faktor ehf.
Number: 15
Paid: 8.3.2023
Expires: 16.4.2024
Payer: Árnason Faktor ehf.
Number: 16
Paid: 7.3.2024
Expires: 16.4.2025
Payer: Árnason Faktor ehf.
Number: 17
Paid: 14.3.2025
Expires: 16.4.2026
Payer: Árnason Faktor ehf.